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Abstract.  Thrombin stimulates cultured endothelial 
ceils (EC) to secrete stored von Willebrand factor 
(vWF), but the signal transduction pathways are poorly 
defined.  Thrombin is known to elevate the concentra- 
tion of intracellular calcium ([Ca2+]i) and to activate 
protein kinase C  (PKC) in EC.  Since both calcium 
ionophores and phorbol esters release vWF, both sec- 
ond messenger pathways have been postulated to par- 
ticipate in vWF secretion in response to naturally oc- 
curring agonists.  We find that in intact human EC, 
vWF secretion stimulated by either thrombin or by a 
thrombin receptor activating peptide, TR(42-55),  can 
be correlated with agonist-induced elevations of 
[Ca2+]i. Further evidence implicating  calcium in the 
signal transduction pathway is suggested by the finding 
that MAPTAM, a cell-permeant calcium chelator,  in 
combination with the extracellular calcium chelator 
EGTA, can inhibit thrombin-stimulated  secretion.  In 
contrast,  the observation that staurosporine (a pharma- 
cological inhibitor of PKC) blocks phorbol ester- but 
not thrombin-stimulated  secretion provides evidence 
against PKC-mediated signal transduction.  To examine 
further the signal transduction pathway initiated by 
thrombin,  we developed novel conditions for minimal 
permeabilization of EC with saponin (4-8/zg/ml  for 
5-15 min at 37~  which allow the introduction of 
small extracellular molecules without the loss of large 
intraceUular proteins and which retain thrombin-stimu- 
lated secretion.  These minimally permeabilized cells 
secrete vWF in response to exogenous calcium,  and 
EGTA blocks thrombin-induced  secretion.  Moreover, 
in these cells, thrombin-stimulated  secretion is blocked 
by a calmodulin-binding  inhibitory peptide but not by 
a  PKC inhibitory peptide.  Taken  together,  these find- 
ings demonstrate that thrombin-stimulated  vWF secre- 
tion is transduced by a rise in [Ca2+]i and provide the 
first evidence for the role of calmodulin in this process. 
T 
HROMBIN, the ultimate  serine protease activated  by 
the coagulation  cascade, is generated at sites of tissue 
injury and inflammation.  In addition to its key role in 
converting  plasma fibrinogen to fibrin,  thrombin influences 
a diverse number of cellular activities.  In human umbilical 
vein endothelial  cells (EC) t, thrombin rapidly induces both 
prostacyclin (Weksler  et al.,  1978) and platelet-activating 
factor (Prescott et al.,  1984) synthesis,  triggers  cell shape 
changes  (Laposata et al.,  1983), and stimulates  the release 
1. Abb~*viations used in this paper:  [Ca2+]i, cytosolic  free calcium con- 
centration;  CaM, calmodulin;  EC, endothelial  cell; MAPTAM, 1,2-bis- 
5-methyl-amino-phenoxyethane-n,n,n'-tetraacetoxy-rnethyl  acetate;  ML-7, 
1-(5-iodonaphthalene-l-sulfonyl)-lH-hexahydro-l,4-diazepine;  MLCK, myosin 
light chain kinase;  MLCK(796-817),  A796RRKWQKTGHAVRAIGRLS- 
SMASlTC; PKC, protein kinase C; TR(42-55), S42FLLRNPNDKYEPF55; 
vWF, von Willebrand factor; W-5, N-(6-aminohexyl)-l-naphthalenesulfon- 
amide;  W-7, N-(6-aminohexyl)-5-chloro-l-naphthalenesulfonamide. 
of von Willebrand  factor (vWF) (Levine et al.,  1982; Loes- 
berg et al., 1983; deGroot et al., 1984) from Weibel-Palade 
bodies,  an  EC-specific  secretory  organelle  (Weibel  and 
Palade,  1964;  Ewenstein  et al.,  1987).  The vWF released 
from the Weibel-Palade body pool is composed chiefly of un- 
usually large  multimers  (Sporn  et al.,  1986;  Ewenstein  et 
al., 1987) which are far more active in inducing platelet ag- 
glutination  (Moake et al., 1986) and bind more avidly to ex- 
tracellular matrix (Sporn et al., 1987) than smaller forms of 
vWE Regulated secretion in EC also results in the transloca- 
tion of a Weibel-Palade body membrane, protein, CD62 (al- 
ternatively  named GMP-140  [McEver and  Martin,  1984], 
PADGEM [Hsu-Lin et al., 1984], or P-selectin  [Bevilacqua 
et al., 1991]), to the plasma membrane (McEver et al., 1989; 
Hattori et al.,  1989a) where it is postulated to function  as 
an adhesion  molecule for neutrophils  (Larsen et al.,  1989; 
Geng et al.,  1990;  Hamburger and McEver,  1990).  Thus, 
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component of endothelial regulation of both hemostasis and 
inflammation. 
The intracellular events that transduce secretion in EC in 
response  to  thrombin  have  yet  to  be  fully  elucidated. 
Receptor-mediated processes in many cell types are thought 
to be initiated by the activation of a phosphatidylinositol- 
specific phospholipase C,  thereby resulting in the genera- 
tion of both inositol 1,4,5-trisphosphate and 1,2-diacylgly- 
cerol from phosphatidylinositol  4,5-bisphosphate (Berridge, 
1984;  Nishizuka, 1984a, b). Thrombin has been shown to 
activate this pathway in cultured human EC  (Jaffe  et al., 
1987; Brock and Capasso, 1988). The thrombin-induced rise 
in inositol 1,4,5-trisphosphate precedes, and is believed to 
trigger, a subsequent rise in cytosolic-free calcium concen- 
tration ([Ca2+]i). The importance of calcium as a  second 
messenger in endothelial secretion of vWF is suggested by 
several  previous  observations.  First,  calcium  ionophore 
A23187,  which elevates [Ca2+]t, also induces vWF release 
(Loesberg et  al.,  1983).  Second,  other  agonists  such as 
histamine (Hamilton and Sims, 1987), vascular permeability 
factor (Brock et al.,  1991), and complement membrane at- 
tack complexes (Hattori et al.,  1989b)  which induce vWF 
release, also raise [Ca2+]t. Third, both thrombin- and his- 
tamine-stimulated vWF release is diminished in the presence 
of extracellular calcium chelators  (deGroot et al.,  1984; 
Hamilton and Sims, 1987). The mechanism by which calcium 
mediates secretion in response to thrombin is not known. 
The 1,2-diacylglycerol generated by thrombin is thought, 
in the presence of elevated [Ca2+]~, to be an endogenous ac- 
tivator of protein kinase C (PKC). A possible role for PKC 
as a mediator of vWF secretion is suggested by the observa- 
tion that the PKC activator, PMA, which does not cause ele- 
vation of [Ca2+]i in human umbilical vein EC,  is a  potent 
secretogogue of vWF (deGroot et al.,  1984;  Ewenstein et 
al.,  1987).  In EC, thrombin has been shown to induce the 
translocation of PKC from cytosolic to membrane fractions 
(Lynch et al., 1990; Heller et al., 1991) and to stimulate the 
phosphorylation of a  myristoylated, alanine-rich C  kinase 
substrate (MARCKS) (Niedel and Blackshear, 1986; Jacob- 
son et al.,  1992).  However,  the role of PKC in thrombin- 
mediated secretion in EC has not been established. 
Using both intact and saponin-permeabilized human um- 
bilical vein EC,  we present evidence here which demon- 
strates that thrombin-stimulated secretion of vWF is medi- 
ated primarily by calcium acting, at least in part, through 
calmodulin (CAM). In contrast, we find that PKC is not pri- 
marily involved in this process. 
Materials and Methods 
Cell Source and Culture 
EC were isolated from three to five human umbilical veins by collagenase 
digestion as previously described (Gimbrone, 1976), pooled, and cultured 
in Medium 199 (M199) containing 20 % heat-inactivated  FCS supplemented 
with penicillin 025 U/ml), streptomycin (125 pg/ml), and 2 mM L-ghitamine 
(all from Gibco Laboratories, Grand Island, NY). Cells were serially pas- 
saged under the conditions of Thornton et al. (1983),  supplementing the 
medium with porcine heparin (100/tg/ml; Sigma Chemical Co., St. Louis, 
MO) and endothelial cell growth factor (50 pg/ml; Upstate Biotechnology, 
Lake Placid, NY).  Tissue culture plasticware,  including T75 flasks, 6- and 
24-well plates (Coming Glass Works, Coming, NY), was coated with gela- 
tin (Difco Laboratories, Detroit, MI) or fibronectin (New York Blood Cen- 
ter, New York, NY) before plating. All cells used in these experiments were 
passaged  tw~ to four times from primary cultures. 
Quantitation of vWF Secretion in Intact EC 
Confluent cultures of EC were washed four times with M199 supplemented 
with 0.1% gelatin (M199/G) then incubated for 15 min with various concen- 
trations of agonist in this buffer. Conditioned medium was then transferred 
to separate tubes, made 5 mM EDTA and 0.1 mM PMSF, and the quantity 
ofvWF released into the conditioned medium was determined by an inhibi- 
tion ELISA employing an avidin-biotin-peroxidase  detection system as pre- 
viously described (Ewenstein et al., 1987). In experiments  involving phar- 
macologic inhibitors, EC were preincubated for 15-20 rain at 37~  with 
these compounds in M199/G before stimulation with agonist.  The quantity 
of vWF released per well of confluent EC varies among different cultures 
and passage levels; in order to allow comparisons among experiments, vWF 
secretion is normalized to maximal thrombin-stimulated  vWF release (in re- 
sponse to a 3 or 10 U/ml thrombin) measured in the same experiment. 
Cell Permeabilization 
Confluent EC monolayers in 24-well tissue culture plates (,'~  ￿  105 cells/ 
well) were washed four times with cytosolic buffer (100 mM KCI, 20 mM 
NaCI, 30 mM Hepes,  1 Mm MgCI2, 100/tM EGTA, and 0.1% gelatin, pH 
7.0), then briefly (5-15 rain) incubated at 37~  with the same buffer contain- 
ing 4-8/~g/mL saponin as indicated. In some experiments, ATP (2.0 mM) 
was added to the permeabilization and stimulation buffers. At this concen- 
tration, ATP did not stimulate vWF release but potentiated secretion in re- 
sponse to thrombin. The precise concentration of saponin required for op- 
timal permeabilization conditions varied with each stock solution and was 
adjusted for each new solution of sapouin to a concentration which pro- 
duced 5-10% release of total lactate dehydrogenase,  as measured by the 
method of Wrobleski  et al.  (1955).  After permeabilization, the saponin- 
containing solution was gently removed and replaced  with cytosolic buffer 
containing the indicated concentrations of agouist.  After an additional  15 
rain at 37~  the medium was removed and vWF quantitated as described 
above.  Calcium-EGTA buffers  were prepared using the formulations  of 
Fabiato and Fabiato (1979) and Miller and Smith (1984), and the free cal- 
cium concentrations in calcium-EGTA buffers ~  10 ~,M were verified using 
a calcium electrode (Orion Research, Inc., Boston, MA). In experiments 
involving pharmacologic inhibitors, inhibitory levels of EGTA,  or peptide 
inhibitors, these compounds were present during saponin treatment and 
agonist stimulation. 
Measurement of  [CW§ 
Changes in [Ca:+]i in suspensions  of human umbilical vein EC (generally 
1.2  x  105 cells/mi) were monitored using fura-2  essentially as described 
by Brock and Capasso (1988).  Fluorescence measurements were made at 
37~  in a SPEX Fluorolog II spectrofluorometer  (model CM-I: SPEX In- 
dustries,  Edison, NJ) equipped with a stirring apparatus and a thermostated 
cuvette holder. The sample cuvette was excited at 340 and 380 nm and emis- 
sion was measured at 505 nm. Autofluorescence  was subtracted from both 
the 340- and 380-nm tracings in each experiment before the calculation of 
the 340/380 ratio and conversion to calcium concentrations. The Kd of 
Ca  2+ for fura-2 in the presence of 1 mM Mg  2+ was assumed to be 224 nM 
(Grynkiewicz  et al.,  1985). 
Materials 
Staurosporine was purchased from Biomol Research Laboratories (Plymouth 
Meeting, PA). W-7, W-5, and ML-7 were purchased from Seilm~aku  America, 
Inc.  (St.  Petersburg,  FL).  Fura-2/AM  was  purchased  from  Molecular 
Probes Inc.  (Eugene,  OR).  MAPTAM was purchased from Calbiochem- 
Behring Corp.  (La Joila,  CA).  Human a-thrombin (2,160 NIH clotting 
U/rag) was a gift of Dr. John W. Fenton II (New York Department of Health, 
Albany, NY).  Bryostatin 1 was prepared by George Pettit (Arizona State 
University,  Tempe, AZ). All other chemicals were from Sigma Chemical 
Co.  (St.  Louis, MO). 
Three peptides were used in these studies. Thrombin receptor activating 
peptide,  TR(42-55), representing the amino-terminal sequence  generated 
by  thrombin  cleavase  of  the  human  DAMI  cell  thrombin  receptor, 
S42FLLRNPNDKYEPF 55 (Vu et al.,  1991), was synthesized by Immuno- 
Dynamics (La Jolla, CA).  MLCK (796-817), a  CaM-inhibiting peptide 
representing chicken smooth muscle myosin  light chain kinase (MLCK) 
residues  A796RRKWQKTGHAVRAIGRLSSMAS17(C), was prepared and 
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PKC(19-31), a PKC inhibitor derived from the pseudosubstrate inhibiting 
domain of the c~-isoform  of bovine brain protein kinase C, R~gFARKGA - 
LRQKNV 31 (Parker et al.,  1986; House and Kemp,  1987) was synthesized 
by the Protein Microsequencing Laboratory, Brigham and Women's Hospi- 
tal. Its inhibitory activity in human umbilical vein EC was independently 
verified in PKC assays (Ritchie et al.,  1991) of EC extracts. 
Results 
Comparison of vWF Secretion and Elevations 
of [Ca'§  Stimulated by Thrombin and Thrombin 
Receptor Activating Peptide 
Thrombin has been previously shown to stimulate elevation 
of [Ca2+]i as measured by calcium-sensitive fiuors in human 
umbilical vein EC (Jaffe et al.,  1987;  Brock and Capasso, 
1988).  Using  fura-2  fluorescence to  measure  [Ca2+]i, we 
compared thrombin-induced vWF secretion with peak eleva- 
tions  of  [CaZ+]i.  In  agreement  with  our  previous  report 
(Zavoico et al.,  1989), we found that thrombin stimulated 
vWF secretion in a dose-dependent fashion (half-maximum 
=0.1  U/ml).  Thrombin-stimulated peak elevation of [Ca2+]~ 
required  somewhat  greater  agonist  concentrations  (half- 
maximum =1.0 U/rnl) (Fig.  1, A). 
To  explore  further  the  relationship  between  thrombin- 
stimulated elevation of [Ca2+]i and vWF secretion, we made 
use of a recently described thrombin receptor activating pep- 
tide,  S42FLLRNPNDKYEPP  5  [TR(42-55)],  representing 
the new amino terminus of the thrombin receptor created by 
cleavage of the peptide bond between R  4~ and S  42 (Vu et al., 
1991). TR(42-55) stimulates platelet aggregation, secretion 
(Vu et al.,  1991), phospholipase C activation (Huang et al., 
1991),  and  EC  [Ca2+]~ elevation,  prostacyclin production 
(Ngaiza and Jaffe,  1991;  GBZ,  our unpublished observa- 
tions),  and  MARCKS  phosphorylation  (Jacobson  et  al., 
1992). We found that TR(42-55) maximally stimulated vWF 
secretion comparable to that observed in response to proteo- 
lytic thrombin. However, in contrast to the actions of throm- 
bin, the stimulation of peak [Ca2§  elevation in response to 
the thrombin receptor activating peptide exhibited concen- 
tration-dependence indistinguishable from that of vWF re- 
lease (half-maximum =40/~M)  (Fig.  1 B).  The observed 
differences between TR(42-55) and thrombin suggest that 
thrombin may partly act to release vWF from cultured EC 
through a  pathway which is independent of the described 
thrombin receptor. 
Effect of PKC Inhibition on Thrombin-stimulated 
Secretion in Intact EC 
The finding that half-maximal activity of thrombin stimu- 
lated  vWF  release  was  less  than  that  observed for peak 
[Ca2+]i elevation, raised the possibility that other signaling 
pathways may be involved in thrombin-mediated secretion in 
EC. In several other cell types, activation of PKC has been 
shown to increase the sensitivity to calcium of the secretory 
process  to  such  an  extent that  secretion occurs  at basal 
[Ca:+]~ (Rink and Knight, 1988). To investigate the possibil- 
ity of a  similar role for PKC in thrombin-stimulated vWF 
secretion,  we  utilized  the  pharmacologic  PKC  activator, 
PMA, and the PKC inhibitor, staurosporine (Tamoaki et al., 
1986).  PMA  stimulated  rapid  vWF  secretion in  a  dose- 
dependent fashion between 5 and 100 nM, a concentration 
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Figure 1. Effect of thrombin and the thrombin receptor-activating 
peptide, TR(42-55)  on vWF secretion (o) and [Ca2+]i elevation 
(e). (A) Stimulation of vWF release and elevation of [Ca2+]~ in re- 
sponse to ~-thrombin.  Data for vWF secretion is expressed as a 
percentage ofvWF released in response to 10 U/ml (means +SEM; 
n = 6). Mean secretion in response to 10 U/ml thrombin was 85.5 
+  16.1 ng/well. [Ca2+]i are expressed as mean (+SEM) increases 
from unstimulated (resting) levels (n = 5-9) in response to the indi- 
cated concentrations of thrombin. The mean resting [Ca2+]i was 75 
5:7.0 nM.  (B)  Stimulation of vWF  secretion and elevation of 
[Ca2+]i in response to TR(42-55).  Data for vWF secretion is ex- 
pressed as the percentage of vWF released in response to 100 t~M 
TR(42-55) (mean + SEM; n = 5). Mean maximal secretion in re- 
sponse to 100 #M TR(42-55) was 97.7 5:18.2 ng/well. [Ca2+]i are 
expressed as mean (+SEM) increases from unstimulated (resting) 
levels (n  =  4-8).  Released vWF was  determined by inhibition 
ELISA and [Ca2+]i was determined by spectrofluorometry as de- 
scribed in Materials and Methods. 
range previously shown to induce the phosphorylation of 
MARCKS, a PKC-specific substrate (Jacobson et al.,  1992) 
and  PKC  translocation  in  EC  (Ritchie  et  al.,  1991). 
Staurosporine significantly blocked vWF  secretion in  re- 
sponse to PMA (Fig. 2 A). In contrast, staurosporine did not 
inhibit thrombin-induced vWF secretion, and in some ex- 
periments actually augmented thrombin-mediated responses 
(Fig.  2  B).  Thus,  staurosporine  distinguishes  thrombin- 
mediated  from  PMA-mediated  secretion.  Moreover,  the 
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Figure 2.  Effect of staurosporine on PMA- and thrombin-stimulated vWF secretion. EC were preincubated for 20 min in the presence 
(o) or absence (e) of staurosporine (30 nM) before the addition of the agonist. The vWF released in response to (A) PMA or (B) thrombin 
at the indicated concentrations was determined by inhibition ELISA (see Materials and Methods). Data points represent the means (+SEM) 
of quadruplicate wells from one of three similar experiments. 
finding that staurosporine does not increase the thrombin 
concentration required for half-maximal secretion, suggests 
that thrombin-stimulated PKC activation is not responsible 
for the observed differences between dose responsiveness to 
vWF secretion and peak [Ca2§  elevation (Fig.  1 A). This 
contention  is  additionally  supported  by  the  finding  that 
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Figure 3. Comparison of bryostatin 1- and PMA-induced vWF se- 
cretion. EC were treated with 3-100 nM concentrations of either 
PMA (o) or bryostatin 1 (o) for 15 min and the quantity of vWF 
released into the conditioned media was determined by inhibition 
ELISA (see Materials and Methods).  Data  points represent the 
means (+SEM) of  triplicate wells from one of  three similar experi- 
ments. 
threshold concentrations of PMA (5 nM) exert no net effect 
on thrombin-mediated vWF secretion in EC over a  broad 
range of thrombin activities (0.03-3 U/ml) (data not shown). 
The  singular  nature  of phorbol  ester-stimulated  vWF 
secretion  was  further  demonstrated  in  experiments  with 
bryostatin 1, a macrocyclic lactone which is known to bind 
to and activate PKC (Kraft et al.,  1986). When tested over 
the concentration range (3-100 nM) previously shown to in- 
duce maximal MARCKS phosphorylation in EC (Jacobson 
et al.,  1992), bryostatin  1 was found to be an ineffective 
stimulator of vWF secretion (Fig, 3). Thus, PKC activation 
per se is not sufficient to stimulate significant endothelial 
vWF secretion. Collectively, these experiments suggest that 
PKC activation does not account for differences in secretion 
caused by thrombin and TR(42-55) and further suggest that 
PKC  is  not primarily  involved in  the  signal  transduction 
pathway utilized by thrombin. 
Involvement of Calcium in Thrombin-stimulated 
Secretion in Intact EC 
To determine if calcium is required for thrombin-stimulated 
secretion, we examined the effects of the cell-permeant cal- 
cium chelator, MAPTAM, and the cell-impermeant calcium 
chelator,  EGTA.  Previously,  MAPTAM  has  been  shown 
both to lower the resting level of [Ca2§  and to blunt the 
rise in [Ca2+]i induced by thrombin in EC (Levin and San- 
tell, 1991). In agreement with a previous report (deGroot et 
al.,  1984),  we  found  that  EGTA  inhibited  thrombin- 
stimulated  secretion by '~50%.  Although  100 #M MAP- 
TAM  was  ineffective  when  tested  alone,  it  completely 
abrogated secretion in the presence of EGTA (Fig. 4). These 
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Tanaka,  1987),  were found to inhibit thrombin-stimulated 
secretion in a dose-dependent manner (Table I). Unexpect- 
edly, both W-7 (but not W-5) and ML-7 also inhibited PMA- 
induced secretion, a process which does not require elevated 
[CaZ+]~. These observations highlight the limited specificity 
of these commonly used pharmacologic inhibitors, and indi- 
cate a need for more specific reagents. 
Figure 4. Effect of MAPTAM and EGTA on thrombin-stimulated 
vWF  secretion.  EC  were  preincubated  with  either  100  /~M 
MAPTAM, 1 mM EGTA or both for 15 min, then stimulated with 
thrombin (1 U/ml) in the presence or absence of  the indicated chela- 
tor(s) for an additional 15 rain. Released vWF was measured by in- 
hibition ELISA (see Materials and Methods). Data are expressed 
as means (+SEM) of triplicate  wells from one of three  similar 
experiments. 
results suggest that calcium is necessary for secretion. How- 
ever, these chelation experiments do not establish whether 
elevations in [Ca2q~ are required. 
Effect of  a Calmodulin Antagonist (W-7) and 
a Myosin Light Chain Kinase Inhibitor (ML-7) on 
Thrombin- and PMA-stimulated Secretion 
To investigate events in thrombin signal transduction distal 
to a stimulated rise in [Ca2+]~, we tested the effects of phar- 
macologic inhibitors of calcium-dependent processes. The 
calcium-binding protein, CaM,  and the Ca2+/CaM-activated 
enzyme, myosin light chain kinase (MLCK), have been im- 
plicated in secretion in a number of cell types (Nelson et al., 
1987; Nakanishi et al., 1989; Kenigsberg and Trifaro, 1985; 
reviewed by Harper,  1988). The close correlation between 
the ability of thrombin to elevate [Ca2+]~ and stimulate vWF 
secretion led us to examine the possible rccle of CaM  and 
MLCK in EC. Both the CaM antagonist W-7 (Hidaka et al., 
1980), but not the less active analogue, W-5 (data not shown), 
Development and Characterization  of  Minimally 
Permeabilized EC with Saponin 
The most specific currently available inhibitors of intraceUu- 
lar signaling pathways are peptides that mimic protein-pro- 
tein or protein-substrate binding sites.  To use these highly 
specific, peptide-based reagents,  we developed a  minimal 
permeabilization protocol in which EC were rendered per- 
meable to these molecules yet retained responsiveness to 
thrombin  stimulation.  Saponin  is  a  cholesterol-dependent 
permeabilizing agent which produces stable pores in plasma 
membranes  of  eukaryotic  cells  (Akiyama  et  al.,  1980; 
Brooks and Carmichael,  1983). Complete permeabilization 
of cells by saponin typically results in the loss of receptor- 
mediated responses. We therefore began our studies by es- 
tablishing  the minimal treatment with saponin that would 
produce permeabilization. The extent of saponin treatment 
was  initially ascertained by measuring  the  release of the 
cytosolic enzyme lactate dehydrogenase during  15 min of 
treatment with varying concentrations of the detergent in a 
cytosolic buffer (Fig.  5 A).  Saponin concentrations of 4-8 
/~g/ml typically produced 5-10% lactate dehydrogenase re- 
lease and retain other large intracellular proteins as analyzed 
by SDS-PAGE of the cultured medium (data not shown). 
This degree of saponin exposure also appeared to permeabi- 
lize the cells to small extracellular molecules such as exter- 
nally applied calcium leading to secretion (Fig. 5 B). Secre- 
tion in response to calcium was concentration dependent, 
beginning at ~1-2/zM and reaching a plateau near 10/zM 
(Fig.  5  C). 
We next determined the effect of saponin incubation time 
at these low concentrations on agonist-induced vWF secre- 
tion. 5-10-min incubations with a low concentration of sapo- 
nin (e.g., 6/zg/ml) preserved responsiveness to thrombin, 
and the magnitude of this response was found to be reprodu- 
cibly augmented by the permeabilization procedure (Fig. 6). 
Table I. Effect of  a Calmodulin Antagonist (W-7) and a Myosin Light Chain Kinase Inhibitor (ML-7) on Thrombin-and 
PMA-stimulated vWF Secretion 
Inhibitor 
W-7  ML-7 
Agonist  None  10 p,M  30/~M  10 p,M  30 p,M 
Thrombin 1.0  U/ml  144  +  9.8  84  5:4.4  20.5  5:1.7  96  5:4.3  36  5:8.5 
(100)  (58)  (14)  (67)  (25) 
PMA 100 nM  71  5:4.2  46.5 5:2.8  6.5  + 2.2  40.5 +  11.2  6.0 5:3.2 
(100)  (65)  (9)  (57)  (9) 
EC were preincubated  in the presence  or absence of the indicated inhibitor  for 15 rain,  then stimulated with either thrombin  (1  U/ml) (expt.  1) or PMA (100 
nM) (expt. 2) for an additional  15 rain. The quantity of stimulated vWF release was derived by subtracting the quantity of vWF released in the absence of both 
agonist and inhibitor (basal secretion) from the measured vWF in each releasate. The data for each agonist are expressed as the mean (+SEM) of triplicate wells 
from one of three  similar experiments.  Numbers in parentheses represent residual agonist-induced vWF secretion (%) in the presence of the indicated inhibitor. 
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Figure 6.  Time-dependent  effect  of saponin  on  agonist-induced 
vWF release.  EC were treated  with 6 #g/mL saponin for the indi- 
cated times and then stimulated for 15 min with either buffer alone 
(B),  100 nM PMA (zx), or 1 U/mL thrombin (o). The quantity of 
vWF released  during the stimulation  period was determined by in- 
hibition ELISA (see Materials  and Methods).  Data points represent 
the  means  (:t:SEM)  of triplicate  wells  from one  of six  similar 
experiments. 
Figure 5. Development and characterization of EC minimally per- 
meabilized  with saponin.  (A) EC were treated  with saponin for 15 
min at the indicated  concentrations and released  lactate dehydrog- 
chase determined as described in Materials  and Methods.  The con- 
centration dependence of saponin treatment varied slightly  among 
four different  experiments  using different  stock solutions;  the re- 
sults  of a representative  experiment are presented.  (B) EC were 
treated with either 2.0 #g/ml (striped) or 4.0 #g/ml (shaded) sap- 
onin for the indicated  time followed by a  15 min stimulation  with 
pCa 5.5 calcium-EGTA buffer (3.2 #M free calcium). Stimulated 
vWF secretion was derived by substracting  vWF released  in the ab- 
sence of added calcium (basal  secretion)  from the total vWF re- 
leased  during the incubation period.  Results  are expressed  as the 
means (+SEM) of triplicate  wells. (C) EC were treated with 6 #g/ 
mL saponin for 10 rain followed by stimulation  with various  cal- 
cium-EGTA buffers (see Materials  and Methods).  The results  are 
the average of duplicate  wells and are representative  of ten similar 
experiments. 
Longer exposure (20 min) to the same concentration of sapo- 
nin, both increased unstimulated vWF release and abolished 
thrombin-mediated  secretion although the response to cal- 
cium was retained (data not shown). In contrast to the initial 
enhancement  of thrombin-stimulated  secretion,  PMA  re- 
sponsiveness was rapidly abolished under these same condi- 
tions  lending  additional  support  to  the  contention  that 
thrombin- and PMA-stimulated vWF secretion are mediated 
by disparate  signaling pathways. 
Thrombin-induced secretion in the permeabilized ceils oc- 
curred in the absence of extracellular calcium.  Cells prela- 
beled with 45Ca exhibited thrombin-induced  calcium efflux 
(KAB; our unpublished observations) indicating the release 
of calcium from intracellular  stores.  To confirm that mini- 
mally-permeabilized EC utilize calcium in the signal trans- 
duction  pathway  of thrombin-induced  vWF  secretion,  we 
performed  experiments  in permeabilized  cells  in the pres- 
Figure 7. Effect of EGTA on thrombin-stimulated  vWF release.  EC 
were treated  with 5 #g/mL saponin for 10 min in the presence of 
EGTA at the indicated  concentrations and then stimulated  with 0.3 
U/mL thrombin for 15 min.  Indicated EGTA concentrations repre- 
sent  the amount of chelator present  in the permeabilization  and 
stimulation  buffers.  The quantity of vWF released  into the condi- 
tioned medium was determined by inhibition  ELISA (see Materials 
and Methods).  The data are represented as the means (+SEM) of 
triplicate  wells  from one of three  similar experiments. 
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EGTA,  in  a  dose-dependent manner,  inhibited thrombin- 
induced secretion (Fig. 7) implying a requirement for cal- 
cium in this response in permeabilized EC. 
Effect ofa Calmodulin Binding Peptide and a PKC 
Inhibitory Peptide on Thrombin-stimulated Secretion 
in Permeabilized  EC 
We utilized our minimally permeabilized EC system to ex- 
amine the influence of two selective peptide inhibitors on 
thrombin-stimulated vWF  secretion.  MLCK(796-817),  a 
peptide CaM antagonist (van Berkum and Means, 1991) pat- 
terned after the CaM binding region of chicken smooth mus- 
cle  MLCK  residues  Ala796-Ala  sl7  (Lukas  et  al.,  1986; 
Kemp et al.,  1987),  and PKC(19-31),  an inhibitor of PKC 
derived from its endogenous pseudosubstrate domain (House 
and Kemp, 1987),  were each introduced into EC by saponin 
permeabilization. We found that 100 #M MLCK(796-817), 
but not PKC(19-31), blocked thrombin-induced secretion by 
~83 % in permeabilized cells (Fig. 8). Access into the intra- 
cellular space was required for inhibition by MLCK(796- 
817) since this peptide had no effect on thrombin-stimulated 
secretion in intact cells. Secretion in response to externally 
applied calcium buffers (3.2/zM) was also blocked (66-82% 
inhibition; n  =  2) by 100 #M MLCK (796-817) but not by 
PKC(19-31)  (data not shown). 
Discussion 
Regulated secretion in eukaryotic cells requires the translo- 
cation of membrane-bound granules from the cytoplasm to- 
ward  the  plasma  membrane and  granule  fusion with the 
plasma membrane. These events are presumed to be regu- 
lated by second messengers generated upon agonist stimula- 
tion (reviewed by Burgess and Kelly, 1987; Harper,  1988; 
Rink and Knight, 1988).  Both calcium and PKC have been 
proposed as second messengers in stimulus-secretion coup- 
ling in EC (Loesberg et al., 1983; deGroot et al., 1984). The 
purpose of our study was to determine the relative impor- 
tance of these two second messenger pathways in thrombin- 
stimulated secretion.  Our data support a  model in which 
thrombin-induced secretion proceeds  primarily  through a 
Ca2§  pathway.  Evidence  for  this  conclu- 
sion comes from experiments in both intact and saponin- 
permeabilized EC. In intact EC, we found a close correlation 
between the dose-response curves for vWF secretion and ele- 
vation of [Ca2+]i and inhibition by the calcium chelators, 
MAPTAM and EGTA. In contrast, the finding that stauro- 
sporine inhibited PMA- but not thrombin-stimulated secre- 
tion  suggests that different pathways are  involved.  In our 
minimally permeabilized cell model that retained thrombin- 
induced secretion, we observed an inhibitory effect of EGTA 
on  thrombin-induced vWF  release.  Most  convincingly, a 
specific CaM-binding peptide MLCK(796-817), but not a 
PKC inhibitory peptide,  PKC(19-31),  inhibited thrombin- 
stimulated secretion in these permeabilized cells. 
Our  studies  confirm previous  reports  that  the  recently 
identified  platelet thrombin receptor (Vu et al., 1991) is func- 
tional in human umbilical vein EC (Ngaiza and Jaffe, 1991). 
We (Zavoico, G.  B.,  M.  Garnberdella, A.  J.  Ritchie, and 
B. M.  Ewenstein,  manuscript  in preparation)  and  others 
(Ngaiza and Jaffe, 1991) have shown that the kinetics of cal- 
Figure 8. Effect  of peptides MLCK(796-817) and PKC(19-31) on 
thrombin-stimulated vWF secretion in permeabilized ceils. EC 
were treated for 15 min with a buffer containing 5 t~g/ml  saponin, 
2 mM ATE and the indicated peptide (100/zM), then stimulated 
for an additional 15 min with 1 U/ml thrombin in the same buffer 
(see Materials and Methods). The results (mean +  SEM; n =  3) 
are expressed as percentage of vWF secreted by thrombin-stimu- 
lated cells in the absence of peptide inhibitors. 
cium  responses  following TR  (42-55)  and  thrombin  are 
similar. Yet a  closer correlation between [Ca2§  and vWF 
secretion  was observed  in response to  a  specific peptide 
agonist, TR(42-55), than to proteolytically active thrombin. 
The reason for this disparity is not known but is unlikely to 
involve PKC because TR(42-55),  like thrombin, stimulates 
PKC activation in this cell type (Jacobson et al.,  1992).  It 
is possible that the processing of EC for [Ca2§  measure- 
ments desensitized the thrombin receptor to stimulation by 
thrombin but not by TR(42-55). Alternatively, the possibil- 
ity exists that thrombin activates additional signal transduc- 
tion pathways, such as those involving cAMP or tyrosine ki- 
nases, which may not be stimulated by TR(42-55) and which 
may potentiate vWF secretion. These possibilities are under 
investigation. 
Plasma membrane permeabilization has been used suc- 
cessfully to investigate stimulus-secretion coupling in many 
cell types (reviewed by Hersey and Perez,  1990)  including 
EC (Suttorp et al.,  1985; Martin and Michaelis, 1990; Van 
Geet et al.,  1990).  Saponin has been used typically at rela- 
tively  high  concentrations  (25-100  /~g/ml)  (Smolen  and 
Stoehr,  1985;  Kimura et al.,  1986),  resulting in maximal 
permeabilization,  with  complete  release  of  lactate  de- 
hydrogenase. Such preparations retain their ability to secrete 
in  a  regulated  manner,  but  only  to  externally  applied 
calcium-EGTA buffers and/or GTP analogues. In contrast, 
our  cell  preparations,  generated by  brief treatment  with 
much lower saponin concentrations (4-8 ~g/ml), retain their 
responsiveness to physiologic agonists such as thrombin and 
are susceptible to the introduction of small macromolecules. 
Our observations suggest that the pore size in such minimally 
permeabilized cells is smaller allowing retention of critical 
signaling components. 
A signal transducing role for calcium in EC secretion was 
previously  inferred  from  experiments  using  ionophores. 
Saponin permeabilization of the plasma membrane followed 
by the application of calcium-EGTA buffers confirmed these 
observations. It appears paradoxical that our saponin-treated 
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sponses yet allow extracellular  calcium to enter and directly 
cause secretion.  We propose that the residual cell membrane 
in permeabilized cells creates a large "unstirred  layer" which 
limits  the rate of [Ca2+]~ equilibration.  As a consequence, 
the cells can still produce transient  and local elevations in 
[Ca2+]~, sufficient  to activate  calcium-dependent  secretory 
components,  before its dissipation  by diffusion  out of the 
cell.  This residual  membrane barrier may also explain  the 
requirement  for tenfold higher levels of calcium in the exter- 
nal medium to cause secretion than are generated  in intact 
cells, as well as the requirement for high concentrations  of 
peptide inhibitors.  Similar  calcium  dose-response curves 
have been reported in many other permeabilized cell prepa- 
rations  (reviewed in Knight  et al.,  1989). 
Our data do not support the primary involvement of PKC 
in thrombin-stimulated  secretion in EC and is thus at vari- 
ance with conclusions drawn from some other cell types. For 
example,  platelet secretion has been shown to parallel  the 
phosphorylation of p47,  a PKC substrate in this  cell type 
(Haslam and Davidson,  1984; Gerrard et al.,  1989).  Simi- 
larly,  Ludowyke et al.  (1990)  have  shown  that  histamine 
secretion  from rat basophilic leukemia cells correlates with 
PKC-mediated  phosphorylation of myosin heavy  and light 
chains. In contrast to the conclusions of those studies and in 
agreement with the data presented in this report, H-7, a phar- 
macological inhibitor of PKC, was shown not to inhibit amy- 
lase secretion from pancreatic acini (Pandol and Schoeffield, 
1986). Similarly, inhibition of PKC by either pharmacologic 
inhibitors such as staurosporine or K252a (Kase et al., 1987) 
or by peptide PKC(19-31)  failed to block agonist-induced 
secretion in bovine adrenal  chromaffin  cells (Terbush  and 
Holz,  1990;  Isosaki et  al.,  1991). Taken together,  these 
studies demonstrate that a primary role of PKC in secretion 
is not a universal  requirement. 
The mechanism by which PMA stimulates vWF secretion 
remains to be defined. PMA induces PKC translocation  from 
cytoplasmic to membrane  fractions in human  EC over a 
range of PMA concentrations  which parallel vWF secretion 
(Ritchie et al.,  1991). Under identical  conditions,  in repli- 
cate wells,  we have failed to observe translocation  of PKC 
in response to thrombin at concentrations  up to  10 U/ml 
(Ritchie,  A. J., B. M. Ewenstein,  and L S. Pober,  unpub- 
lished observations).  Furthermore, as reported here, bryo- 
statin  1 can activate PKC without inducing  vWF secretion. 
Cumulatively, these observations provide support for the no- 
tion that PKC activation in response to PMA may be qualita- 
tively different from that seen in response to naturally occur- 
ring  agonists  such as thrombin (Thomas  et al.,  1987). 
The observation that PMA responsiveness  is lost in our 
saponin-permeabilized  EC preparation may be explained ei- 
ther by the loss of PKC activity or by specific inhibition  of 
the phorbol ester by the detergent.  Recent experiments  have 
shown that PMA stimulates  MARCKS phosphorylation in 
saponin-permeabilized  EC and that PKC(19-31) inhibits this 
response (Birch,  K. A., J. S. Pober, and B. M. Ewenstein, 
manuscript in preparation). Therefore, the failure of PKC(19- 
31) to block thrombin-induced  vWF secretion further sup- 
ports the argument that PKC activation is not an essential fea- 
ture of this process. 
A  role for calmodulin  in stimulus-secretion  coupling  in 
other cell types has  been demonstrated using  pharmaco- 
logical  inhibitors  of calmodulin  such  as W-7 and trifluo- 
perizine (Kimura  et al.,  1986; reviewed in Harper,  1988; 
Trifaro and Fournier,  1987). In addition,  anti-CaM antibod- 
ies were shown to block cortical granule fusion in sea urchin 
oocytes (Steinhardt  and Alderton,  1982) and acetylcholine- 
and K+-induced catecholamine secretion in chromaflin cells 
(Kenigsberg  and Trifaro,  1985).  In contrast to results  ob- 
tained by Terbush and I-Iolz (1990) in which they observed 
no effect of Ca:+/CaM Kinase II(292-317),  another  CaM- 
binding peptide, on Ca  2+- or PMA-induced exocytosis from 
bovine adrenal chromaffin cells, we found that MLCK(796- 
817), blocked thrombin-stimulated  secretion in minimally- 
permeabilized EC.  We have since observed similar  inhibi- 
tion by other CaM-binding  peptides (Birch,  K.  A., J.  S. 
Pober, and B. M. Ewenstein, manuscript in preparation). 
Ca2+/CaM may regulate secretion at multiple  sites along 
the secretory pathway. For example, it may be involved in ac- 
tivating contractile elements such as MLCK which may play 
a role in granule movement from the cytoplasm to the plasma 
membrane.  The phosphorylation of myosin light  chain  by 
MLCK correlates with the exocytotic process in a number 
of other cell types (Inagald et al., 1984; Saitoh et al., 1986) 
and  more  recently  in  EC  retraction  (Wysolmerski  and 
Lagunoff,  1990), a process with which secretion may share 
certain common features.  In addition,  pharmacological  in- 
hibitors of MLCK, ML-7 and ML-9 (Hidaka  and Tanaka, 
1987), have been used to demonstrate the potential involve- 
ment of MLCK in catecholamine  secretion from adrenal 
chromaffin  cells (Nagatsu  et al.,  1987; Nakanishi  et al., 
1989).  However, the inhibition  by ML-7 and W-7 of both 
PMA- and thrombin-induced  vWF secretion in EC suggests 
that either the signal transduction  pathway utilized by PMA 
involves  Ca2+/CaM and  possibly  MLCK  at  some  distal 
step, or more likely, that these agents block both calmodulin- 
dependent and independent  kinases.  The recent finding that 
W-7  inhibits  phorbol  ester-induced  contraction  in  aortic 
smooth muscle cells by interfering  with PKC translocation 
(Chuprun  et al., 1991) lends support to the latter interpreta- 
tion.  Thus,  these pharmacologic  inhibitors  are of limited 
utility in accessing the role of calmodulin and MLCK in sig- 
nal transduction  pathways, and such limited utility empha- 
sizes the value of peptide-based, specific inhibitors. 
Our observation that MLCK(796-817) blocks thrombin- 
stimulated  secretion  in  permeabilized  EC  suggests  that 
Ca2+/CaM may act,  at least in part,  through  the activation 
of MLCK or other Ca2+/CaM-dependent  protein kinases. 
Alternatively,  Ca2+/CaM may be involved in the dissolution 
of cortical actin networks which, under basal conditions,  in- 
hibit granule  fusion with  the plasma membrane.  Previous 
studies have shown that CaM inhibits  the interaction  of fo- 
drin, an actin-binding  protein, with cortical actin filaments 
(Harris and Morrow, 1990) and antisera against brain-fodrin 
has been reported to partially inhibit  Ca2+-induced secre- 
tion from permeabilized adrenal chromaffin cells (Perrin  et 
al., 1987). Fodrin, protein 4.1 and other actin binding pro- 
teins have been identified in EC (Leto et al.,  1986; Pratt et 
al., 1984; J. S. Morrow, personal communication)  and other 
secretory cells and may play a role in regulated  secretion 
(reviewed by: Burgoyne,  1990; Trifaro,  1987; and Aunis and 
Bader,  1988). 
In summary, the experiments  reported here using both in- 
tact cells and a novel permeabilized preparation  of human 
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ond messenger system for transducing thrombin-stimulated 
vWF secretion. In contrast, PKC activity is not essential to 
this process although an adjuctive role cannot be ruled out. 
Finally, the thrombin-responsive, minimally-permeabilized 
preparation of EC described here should prove useful in fu- 
ture studies of stimulus-response coupling in this cell type. 
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